BIOATLA INC. - COMMON STOCK

BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

27 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Participate in the Jefferies Global Healthcare Conference

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 16:05:00 By Nasdaq GlobeNewswire

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

14 May 2024 15:05:00 By Nasdaq GlobeNewswire

BioAtla to Participate in the Citizens JMP Life Sciences Conference

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

07 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 15:35:00 By Nasdaq GlobeNewswire

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

26 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

19 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

07 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

20 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

13 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

06 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

05 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

30 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

07 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

BioAtla to Participate in the Jefferies London Healthcare Conference

06 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award

12 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

10 Oct 2023 06:30:00 By Nasdaq GlobeNewswire